COVID-19: Drugs in Development


The COVID-19 outbreak, which started in December 2019 in Wuhan City, China, was declared a "Public Health Emergency of International Concern" by the WHO on January 30, 2020. The outbreak was characterized as a pandemic on March 11, 2020.

Currently, there are no drugs to treat COVID-19, caused by the novel coronavirus SARS-CoV-2.

Listed below are companies that are in the race to find a treatment or vaccine for the novel coronavirus.

Subscribe to RTT Intelligent Investor for FREE 7-Day Trial with complete access to COVID-19 Drugs in Development Calendar.

Company Name
Current Stage
Next Milestone
Last Updated
Sinovac Biotech Ltd.
COVID-19 Vaccine against Ómicron strain
Chilean Public Health Institute has cleared Phase 2 study of COVID-19 Vaccine against Omicron strain- reported on Sept. 6, 2022.
Vaxart, Inc.
VXA-CoV2-1.1-S- S-only oral COVID-19 vaccine candidate
Top-line data from the first part of a two-part Phase II study of Wuhan S-only oral pill COVID-19 vaccine candidate, VXA-CoV2-1.1-S were reported on Sept. 01, 2022. The study met its primary safety and secondary immunogenicity endpoints.
Kinarus Therapeutics Holding AG
KIN001- to treat Covid-19.
Phase 2 study of KIN001 dubbed KINFAST in Covid-19 outpatients was initiated- reported on Aug. 29, 2022.

Phase 2 study of KIN001 dubbed KINETIC in hospitalized Covid-19 patients is ongoing.
Interim data from Phase 2 KINETIC trial in hospitalized Covid-19 patients is expected in the third quarter of 2022.

Get Full Access to latest records of COVID-19 Drugs in Development Calendar by subscribing to RTT Intelligent Investor with FREE 7-Day Trial. (No Credit Card Required)

Editors Pick
The U.S. Food and Drug Administration said it now intends to review only a small subset of new emergency use authorization or EUA requests for diagnostic tests. As per an updated COVID-19 test policy with a view to ensure continued access to tests, the regulator further urged developers of all test types seeking marketing authorization to pursue traditional premarket review for most test types. Netflix, Inc. said it is adding a new feature to offer a more personalized mobile games experience on the platform. In a statement, Sophia Yang, Product Manager, Mobile Games, said the company is rolling out the ability to create game handles, with which members will be able to create a unique public username. This can be used across all Netflix games. General Motors Co. has delayed its plan to require employees to return to office many days a week until next year, reports said citing an internal memo signed by CEO Mary Barra. Last week, the company had announced that corporate workers would be required to return to respective offices at least three days a week, beginning later this year, as the COVID-19 pandemic eases.